ArticleGene therapy2004
Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
Article in Gene therapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- Pulsed focused ultrasound alters the proteomic profile of the tumor microenvironment in a syngeneic mouse model of glioblastoma.Journal of neuro-oncology · 2024Article
- Genetically engineered mesenchymal stem cells: targeted delivery of immunomodulatory agents for tumor eradication.Cancer gene therapy · 2020Review
- Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy.Oncotarget · 2017Review
- Showing the Way: Oncolytic Adenoviruses as Chaperones of Immunostimulatory Adjuncts.Biomedicines · 2016Review
- Mutations of the human interferon alpha-2b gene in brain tumor patients exposed to different environmental conditions.Cancer gene therapy · 2015Review
- Immunocompetent murine models for the study of glioblastoma immunotherapy.Journal of translational medicine · 2014Review
- An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma.Expert review of vaccines · 2013Review
- Integration of epidemiology, immunobiology, and translational research for brain tumors.Annals of the New York Academy of Sciences · 2013Article
- Improved Adeno-associated Viral Gene Transfer to Murine Glioma.Journal of genetic syndromes & gene therapy · 2013Article
- Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics.Neoplasia (New York, N.Y.) · 2012Article
- Gene therapy and targeted toxins for glioma.Current gene therapy · 2011Review
- Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model.Cancer immunology, immunotherapy : CII · 2011Review
- Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment.Neuro-oncology · 2010Article
- Dendritic cell therapy of high-grade gliomas.Brain pathology (Zurich, Switzerland) · 2009Review
- Immunotherapy of diffuse gliomas: biological background, current status and future developments.Brain pathology (Zurich, Switzerland) · 2009Review
- Magnetic resonance imaging-guided adoptive cellular immunotherapy of central nervous system tumors with a T1 contrast agent.Magnetic resonance in medicine · 2009Article
- Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10.Cancer research · 2009Article
- A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy.Gene therapy · 2009Article
- In vivo bioluminescence imaging in an experimental mouse model for dendritic cell based immunotherapy against malignant glioma.Journal of neuro-oncology · 2009Article
- Gene delivery into malignant glioma by infectivity-enhanced adenovirus: in vivo versus in vitro models.Neuro-oncology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
Abstract
Effective presentation of tumor antigens by dendritic cells (DCs) is considered to be essential for the induction of antitumor T-cell responses. Apoptotic and necrotic tumors have been noted to be a robust antigen source for DCs. Because glioma cells undergo apoptosis after transfection with the type I interferon (IFN) gene and type I IFNs promote the stimulatory activity of DCs, we hypothesized that transfection of glioma cells with type I IFN genes and provision of DCs would promote particularly effective antitumor activity by both facilitating apoptosis of glioma cells and the presentation of the glioma antigens, thereby inducing specific immune responses against glioma cells. We have previously reported the proof of this hypothesis in vitro and in a subcutaneous tumor model. Here we report an extension of this approach in intracranial (i.c.) gliomas using adenoviral IFN-alpha (Ad-IFN-alpha) vector. Mice bearing day-5 i.c. GL261 glioma received sequential intratumoral (i.t.) delivery of Ad-IFN-alpha and bone marrow-derived syngeneic DCs. This treatment prolonged survival in that nine of 17 animals survived long term (> 60 days versus 0 of 10 control animals). Specific CTL activity was demonstrated following this regimen in the cervical lymph nodes, and the therapeutic efficacy was dependent upon CD8+ cells. Furthermore, these animals were protected against subsequent re-challenge with GL261 gliomas. DCs injected i.t. survived in the tumor and migrated into cervical lymph node. In vitro migration assays revealed the ability of DCs to migrate toward the tumor, suggesting that i.t. injected DCs migrate through the glioma. Taken together, this combination of gene therapy and cellular immunotherapy may be an effective future strategy for treating human gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.